Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

meRfi® AI Chat

CD30 CAR-T & Hodgkin Lymphoma

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

(Login)

Navigation

Recent advancements have been made in targeting antigens such as CD30, which is commonly expressed on Reed-Sternberg cells, offering a new therapeutic avenue for R/R Hodgkin Lymphoma. However, the application of CAR-T therapy in Hodgkin Lymphoma has been limited by the downregulation of HLA molecules on Hodgkin Reed-Sternberg (HRS) cells, which helps these cells evade immune detection.
Ho et al. 2021 Blood Adv. 5(20): 4291-4302
Meier et al. 2022 J Pers Med. 12(2): 197

CD30 CAR-T cells have demonstrated promising results in early-phase clinical trials, showing the ability to induce responses in patients with R/R HL
Ho et al. 2021 Blood Adv. 5(20): 4291-4302
Meier et…

References (Sources)

Adoptive T-cell therapy for Hodgkin lymphoma
Ho et al. 2021 Blood Adv. 5(20): 4291-4302
Review
The Emerging Role of CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma
Meier et al. 2022 J Pers Med. 12(2): 197
Review

AI Chat

7/1/2026

Chat with our artificial intelligence:

Start chat!

CD30 CAR-T & Hodgkin Lymphoma

Welcome to meRfi Microbiome!

Navigation

Contents

References (Sources)

AI Chat